Does Rallies summarize ONCO news?

Yes. Rallies summarizes ONCO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.

Is ONCO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ONCO. It does not provide personalized investment advice.

ONCO (Onconetix, Inc. Common Stock) Stock Analysis - News

Onconetix, Inc. Common Stock (ONCO) is a publicly traded Healthcare sector company. As of May 19, 2026, ONCO trades at $0.16 with a market cap of $4.29M and a P/E ratio of -0.06. ONCO moved -47.69% today. Year to date, ONCO is -96.20%; over the trailing twelve months it is -99.15%. Its 52-week range spans $0.31 to $2,762.50. Rallies surfaces ONCO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What changed in ONCO news today?

Onconetix Announces 1-for-10 Reverse Split, Shares Jump 23.65% after Proclarix Trial Launch: Onconetix will implement a 1-for-10 reverse split on May 21, cutting shares outstanding from about 11.4 million to 1.14 million to comply with Nasdaq’s $1 minimum bid requirement. Shares then surged 23.65% after hours to $0.38 following new peer-reviewed publications and launch of a U.S. Proclarix validation trial with Labcorp.

ONCO Key Metrics

Key financial metrics for ONCO
Metric	Value
Price	$0.16
Market Cap	$4.29M
P/E Ratio	-0.06
EPS	$-5.14
Dividend Yield	0.00%
52-Week High	$2,762.50
52-Week Low	$0.31
Volume	91.30M
Avg Volume	0
Revenue (TTM)	$735.20K
Net Income	$-9.70M
Gross Margin	79.63%

Latest ONCO News

Onconetix Announces 1-for-10 Reverse Split, Shares Jump 23.65% after Proclarix Trial Launch — May 19, 2026
Onconetix’s Proclarix® Cuts Unnecessary Biopsies in 371-Patient Study; U.S. Trial Begins — May 13, 2026
First Vinci AI Vision Robot Delivered to Ericsson, Onconetix to Acquire Realbotix — Apr 9, 2026
Onconetix Readies 19 Robot Deliveries and H2 2026 Acquisition of Realbotix — Apr 2, 2026
Onconetix Appoints David White as CEO to Lead Realbotix Acquisition — Mar 31, 2026

Recent ONCO Insider Trades

HRT FINANCIAL LP sold 49.71K (~$34.30K) on Apr 21, 2026.
HRT FINANCIAL LP sold 94.46K (~$70.85K) on Apr 20, 2026.
HRT FINANCIAL LP bought 34.64K (~$25.28K) on Apr 17, 2026.

ONCO Analyst Consensus

ONCO analyst coverage data. Average price target: $0.00.

Common questions about ONCO

What changed in ONCO news today?: Onconetix Announces 1-for-10 Reverse Split, Shares Jump 23.65% after Proclarix Trial Launch: Onconetix will implement a 1-for-10 reverse split on May 21, cutting shares outstanding from about 11.4 million to 1.14 million to comply with Nasdaq’s $1 minimum bid requirement. Shares then surged 23.65% after hours to $0.38 following new peer-reviewed publications and launch of a U.S. Proclarix validation trial with Labcorp.
Does Rallies summarize ONCO news?: Yes. Rallies summarizes ONCO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ONCO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ONCO. It does not provide personalized investment advice.